Cargando…

National neonatal screening program for hemoglobinopathies: how far have we advanced?()

Detalles Bibliográficos
Autor principal:	da Fonseca, Silvana Fahel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2014
Materias:	Scientific Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207923/ https://www.ncbi.nlm.nih.gov/pubmed/25031161 http://dx.doi.org/10.1016/j.bjhh.2014.05.012

Ejemplares similares

Critical analysis of the neonatal screening program for hemoglobinopathies
por: Moreira, Raphaela Martins Muniz, et al.
Publicado: (2011)

Offline: COVID-19—what have we learned so far?
por: Horton, Richard
Publicado: (2020)

Open questions: genomics and how far we haven’t come
por: Adams, Michael
Publicado: (2013)

Open questions: How many genes do we have?
por: Salzberg, Steven L.
Publicado: (2018)

Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021)

α-chain hemoglobin variants with electrophoretic mobility similar to that of hemoglobin S in newborn screening programs
por: Sonati, Maria de Fátima
Publicado: (2013)

Neonatal screening program for hemoglobinopathies in the city of São Carlos, state of São Paulo, Brazil: analysis of a series of cases
por: Silva, Camila de Azevedo, et al.
Publicado: (2015)

Paediatric Surgery on the African Continent: How Far Have We Come; How Far Can We Go?
por: Numanoglu, Alp
Publicado: (2023)

Myeloid leukemia: are we getting better?()
por: Hamerschlak, Nelson
Publicado: (2015)

Multisystem inflammatory syndrome in children and complete atrioventricular block: What have we learned so far and where do we go from here?
por: Clark, Bradley C, et al.
Publicado: (2021)

Follow-up of children with hemoglobinopathies diagnosed by the Brazilian Neonatal Screening Program in the State of Pernambuco
por: Soares, Ana Caroline Novaes, et al.
Publicado: (2014)

Prevention of diabetes: How far have we gone?
por: Ramachandran, Ambady, et al.
Publicado: (2014)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?
por: Caimi, Paolo F., et al.
Publicado: (2014)

Hodgkin's lymphoma in developing countries: can we go further?()
por: Gaiolla, Rafael Dezen
Publicado: (2017)

Pregnancy in sickle cell disease – do we know what to expect?()
por: Fertrin, Kleber Yotsumoto
Publicado: (2014)

Compound heterozygosity for hemoglobin S and D: what do we need to know?()
por: Bonini-Domingos, Claudia Regina
Publicado: (2016)

Biomaterials for Testicular Bioengineering: How far have we come and where do we have to go?
por: Horvath-Pereira, Bianca de Oliveira, et al.
Publicado: (2023)

Potential mouth rinses and nasal sprays that reduce SARS-CoV-2 viral load: What we know so far?
por: de Toledo Telles-Araujo, Gabriel, et al.
Publicado: (2020)

Methemoglobinemia in children: how to explain the results?
por: Naoum, Paulo Cesar
Publicado: (2012)

Rational use of blood: how to do it?
por: Moraes-Souza, Helio
Publicado: (2013)

Intravenous iron therapy: how far have we come?
por: Cançado, Rodolfo Delfini, et al.
Publicado: (2011)

Imaging of the unstable plaque: how far have we got?
por: Matter, Christian M., et al.
Publicado: (2009)

Best Pharmaceuticals for Children: How Far Have We Come?
por: Mazer-Amirshahi, Maryann, et al.
Publicado: (2014)

Understanding Bioluminescence in Dinoflagellates—How Far Have We Come?
por: Valiadi, Martha, et al.
Publicado: (2013)

Candida glabrata Biofilms: How Far Have We Come?
por: Rodrigues, Célia F., et al.
Publicado: (2017)

Gene Delivery to the Skin – How Far Have We Come?
por: Ain, Qurrat Ul, et al.
Publicado: (2021)

Overcoming Shellfish Allergy: How Far Have We Come? †
por: Wai, Christine Y.Y., et al.
Publicado: (2020)

Calcium imaging analysis – how far have we come?
por: Robbins, Miranda, et al.
Publicado: (2021)

Treatment-resistant schizophrenia: How far have we traveled?
por: Pandey, Ambu, et al.
Publicado: (2022)

Immigration and screening programs for hemoglobinopathies in Italy, Spain and Turkey
por: Canatan, Duran, et al.
Publicado: (2021)

Comment on: Transfusion practices in a neonatal intensive care unit in a Brazilian town()
por: dos Santos, Amelia Miyashiro Nunes
Publicado: (2014)

We need to talk more about transfusion-transmitted malaria in Plasmodium vivax endemic areas()
por: Lacerda, Marcus Vinícius Guimarães, et al.
Publicado: (2014)

ABO isohemagglutinin titration or hemolysin test: what should we do to reduce the risk of passive hemolysis?()
por: Castilho, Lilian
Publicado: (2015)

Platelet and reticulocyte new parameters: why and how to use them?()
por: Grotto, Helena Zerlotti Wolf
Publicado: (2016)

In Search of a Data-in-Once, Electronic Health Record-Linked, Multicenter Registry—How Far We Have Come and How Far We Still Have to Go
por: Marsolo, Keith
Publicado: (2013)

Effectiveness of confidential unit exclusion for screening blood donors
por: Eder, Anne
Publicado: (2011)

Neuropsychiatric Consequences of COVID-19: What Do We Know So Far?
por: Machado, Sergio, et al.
Publicado: (2022)

Anti-Trypanosoma cruzi inconclusive results in blood donor screening
por: Otani, Márcia Mitiko
Publicado: (2012)

A novel strategy for the screening for platelet refractoriness: prospects and limitations
por: Arruda, Valder R.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6crmrj5f5276b84vb77r9c6gp8